Clinical Trial Update: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous CT-P13 (infliximab) for moderately to severely active Crohn's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CT-P13 (infliximab) (infliximab)

Snippet

Sponsor: Celltrion | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-10-23